Get access

Onychomycosis in Immunosuppressed Children Receiving Chemotherapy

Authors

  • Maria Teresa García-Romero M.D.,

    Corresponding author
    1. Department of Dermatology, Hospital General Dr. Manuel Gea González, Mexico City, Mexico
    • Address correspondence to Maria Teresa García Romero, M.D., Hospital General Dr. Manuel Gea González, Calzada de Tlalpan 4800, Sección XVI, México City 14080, Mexico, or e-mail: teregarro@gmail.com

    Search for more papers by this author
  • Enrique L. Aguilar M.D.,

    1. Department of Oncology, Hospital General Dr. Manuel Gea González, Mexico City, Mexico
    Search for more papers by this author
  • Roberto Arenas M.D.

    1. Mycology Section, Hospital General Dr. Manuel Gea González, Mexico City, Mexico
    Search for more papers by this author

Errata

This article is corrected by:

  1. Errata: Erratum Volume 31, Issue 6, 759, Article first published online: 25 November 2014

Abstract

Onychomycosis in children has a low incidence worldwide; certain conditions such as immunosuppression have been described as risk factors for it. We studied 72 children receiving chemotherapy for different neoplasms to determine the frequency of onychomycosis. Only one patient had white superficial onychomycosis from Trichophyton rubrum, a frequency of 1.3%, not different from that reported in healthy patients.

Ancillary